Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective?

Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective?

Abstract Objective To test the hypothesis that treatment decisions (treatment with a PCSK9-mAb versus no treatment) are both more effective and more cost-effective when based on estimated lifetime benefit than when based on estimated risk reduction over 10 years. Methods A microsimulation model was...

Full description

Bibliographic Details
Main Authors: Gijs F. N. Berkelmans, Jacoba P. Greving, Yolanda van der Graaf, Frank L. J. Visseren, Jannick A. N. Dorresteijn
Format: Article
Language:English
Published: BMC 2020-04-01
Series:Diagnostic and Prognostic Research
Subjects:
Lifetime benefit
Lifetime expectancy estimation
Cost-effectiveness
Prevention
PCSK9-mAb
Online Access:http://link.springer.com/article/10.1186/s41512-020-00072-5

Internet

http://link.springer.com/article/10.1186/s41512-020-00072-5

Similar Items